AMEX · PLX
Healthcare · Biotechnology
$2.71
Up+$0.02 (+0.74%)
Updated Oct 6, 2026, 10:37 PM
SID Score
4.0/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance · PLX
1M range · 20 trading sessions · Daily adjusted prices
Prices through Oct 5, 2026
PLX closed at $2.71 after 20 trading sessions, up 2.26% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 5, 2026 | $2.68 | $2.74 | $2.65 | $2.71 | 984.06K |
| Oct 2, 2026 | $2.70 | $2.72 | $2.64 | $2.71 | 947.41K |
| Oct 1, 2026 | $2.77 | $2.77 | $2.60 | $2.68 | 1.59M |
| Sep 30, 2026 | $2.69 | $2.815 | $2.68 | $2.76 | 836.26K |
| Sep 29, 2026 | $2.69 | $2.735 | $2.6803 | $2.69 | 898.56K |
| Sep 28, 2026 | $2.71 | $2.72 | $2.61 | $2.69 | 832.82K |
| Sep 25, 2026 | $2.76 | $2.775 | $2.70 | $2.72 | 386.03K |
| Sep 24, 2026 | $2.78 | $2.8167 | $2.73 | $2.75 | 302.7K |
| Sep 23, 2026 | $2.84 | $2.8495 | $2.765 | $2.80 | 586.41K |
| Sep 22, 2026 | $2.75 | $2.84 | $2.75 | $2.84 | 854.9K |
| Sep 21, 2026 | $2.71 | $2.78 | $2.69 | $2.75 | 471.38K |
| Sep 18, 2026 | $2.68 | $2.715 | $2.66 | $2.69 | 1.25M |
| Sep 17, 2026 | $2.71 | $2.725 | $2.68 | $2.70 | 321.89K |
| Sep 16, 2026 | $2.68 | $2.705 | $2.62 | $2.68 | 1.06M |
| Sep 15, 2026 | $2.75 | $2.75 | $2.64 | $2.66 | 812.74K |
| Sep 14, 2026 | $2.63 | $2.79 | $2.6201 | $2.77 | 952.16K |
| Sep 11, 2026 | $2.74 | $2.75 | $2.615 | $2.64 | 646.81K |
| Sep 10, 2026 | $2.66 | $2.735 | $2.64 | $2.73 | 782.52K |
| Sep 9, 2026 | $2.68 | $2.68 | $2.595 | $2.67 | 580K |
| Sep 8, 2026 | $2.66 | $2.67 | $2.60 | $2.65 | 908.36K |
The latest Smart Investors Daily articles mentioning PLX.
Company
Market Activity
Research & News
PLX research
Company profile and research snapshot.
Protalix BioTherapeutics Inc is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system or ProCellEx. It has developed taliglucerase alfa for the treatment of Gaucher disease. The company's products also treat diseases like Fabry disease and cystic fibrosis. The company's primary sources of revenue include its sales of BioManguinhos alfataliglicerase in Brazil and of drug substances to Pfizer under its Amended Pfizer Agreement. The company's pipeline consists of ELFABRIO, Uricase, and Long Acting DNase I.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Sep 9, 2026 | HC Wainwright & Co. | Buy | — |
| Mar 19, 2026 | HC Wainwright & Co. | Buy | — |
| Nov 21, 2025 | HC Wainwright & Co. | Buy | — |
| Feb 3, 2025 | HC Wainwright & Co. | Buy | — |
| Nov 14, 2023 | HC Wainwright & Co. | Buy | — |
No generated briefing is available yet.
SeekingAlpha · Sep 16, 2026
Protalix BioTherapeutics, Inc. (PLX) Morgan Stanley 24th Annual Global Healthcare Conference September 16, 2026 1:05 PM EDTCompany ParticipantsGilad Mamlok...
Benzinga · Sep 9, 2026
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Protalix BioTherapeutics (AMEX:PLX) with a Buy and maintains $12 price target.
Yahoo · Sep 8, 2026
Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the discovery, development, production, and commercialization of innovative therapeutics for rare diseases with significant unmet needs, today announced that Gilad Mamlok, Senior Vice President and Chief Financial Officer, is scheduled to participate in the following two upcoming investor conferences in New York City, New York:
SeekingAlpha · Aug 12, 2026
Protalix BioTherapeutics, Inc. (PLX) Q2 2026 Earnings Call August 12, 2026 8:00 AM EDTCompany ParticipantsMike Moyer - Managing DirectorDror Bashan -...
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning PLX.
